Axsome Therapeutics (AXSM) Gains from Sales and Divestitures (2021 - 2026)

Axsome Therapeutics has disclosed Gains from Sales and Divestitures across 6 years of filings, most recently posting $286136.0 for Q1 2026.

• Gains from Sales and Divestitures for Q1 2026 came in at $286136.0, up 17.13% year-over-year; the trailing twelve-month figure through Mar 2026 was $286136.0 (up 17.13% YoY), and the FY2025 annual result was $321470.0, up 20.05% from the prior year.
• Gains from Sales and Divestitures came in at $286136.0 for Q1 2026 at Axsome Therapeutics, down from $321470.0 in the prior quarter.
• In the past five years, Gains from Sales and Divestitures ranged from a high of $321470.0 in Q4 2025 to a low of $61581.0 in Q1 2022.
• The 5-year median for Gains from Sales and Divestitures is $210490.0 (2024), against an average of $196227.4.
• Across the five-year window, Gains from Sales and Divestitures jumped 1854.33% in 2022 and climbed 16.06% in 2025, its largest moves.
• Axsome Therapeutics' Gains from Sales and Divestitures stood at $81639.0 in 2022, then soared by 138.15% to $194425.0 in 2023, then jumped by 37.73% to $267779.0 in 2024, then gained by 20.05% to $321470.0 in 2025, then dropped by 10.99% to $286136.0 in 2026.
• The last three Gains from Sales and Divestitures figures came in at $286136.0 (Q1 2026), $321470.0 (Q4 2025), and $295835.0 (Q3 2025), per Business Quant data.